Sequential Gemcitabine plus Docetaxel Is the Standard Second-line Intravesical Therapy for BCG-unresponsive Non-muscle-invasive bladder cancer: Pro.

Docetaxel and gemcitabine have different mechanisms of action, are well tolerated as monotherapies, and are affordable. This combination represents a good option for the second-line, bladder-preserving standard of care for non-muscle-invasive bladder cancer unresponsive to bacillus Calmette-Guérin.

European urology focus. 2021 Sep 27 [Epub ahead of print]

Mathieu Roumiguié, Peter C Black

Department of Urology, CHU Institut Universitaire du Cancer de Toulouse, Toulouse, France; Vancouver Prostate Centre, Department of Urologic Sciences, University of British Columbia, Vancouver, Canada. Electronic address: ., Vancouver Prostate Centre, Department of Urologic Sciences, University of British Columbia, Vancouver, Canada.

email news signup